Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
Conditions
Interventions
Live, attenuated, dengue serotype 1, 2, 3, 4 virus
Placebo: (NaCl) 0.9% solution
Locations
22
Brazil
Fortaleza, Ceará, Brazil
Vitória, Espírito Santo, Brazil
Goiânia, Goiás, Brazil
Campo Grande, Mato Grosso do Sul, Brazil
Natal, Rio Grande do Norte, Brazil
Aguazul, Casanare Department, Colombia
Start Date
June 8, 2011
Primary Completion Date
November 1, 2014
Completion Date
March 5, 2018
Last Updated
March 21, 2022
NCT06579755
NCT04486638
NCT07007585
NCT06665035
NCT07040202
NCT06388785
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions